Home » Newsletters » BioWorld Science

BioWorld Science

March 13, 2003

View Archived Issues

Company profile: Enact Pharma

Quinoline Src kinase inhibitors in AstraZeneca pipeline

Novel agents for enhancing DNA-damaging antitumor activity

Dual 5-HT reuptake inhibitors/5-HT1A agonists discovered at Wyeth

Lilly researchers claim piperidine-containing factor Xa inhibitors

Novel antidiabetic agents covered by Dr. Reddy's patent

Merck presents new aldose reductase inhibitors

Novel series of antiangiogenic tyrosine kinase inhibitors for cancer and other disorders

Merck presents new antithrombotic thrombin receptor antagonists

BMS claims buspirone metabolite enantiomers with utility in anxiety and depression

XenoPort receives SBIR grant to aid in identification of drug transport pathways

Schwarz's year-end results exceed expectations

Sumitomo licenses Glucophage in Japan

Vical anthrax vaccine to enter clinical testing by year-end 2003

Potential use of abetimus sodium in the prevention of SLE-associated renal flare

Gadobutrol perfusion-weighted imaging in Alzheimer's disease

Transarterial 131I-lipiodol in HCC

Ariad focuses resources on anticancer candidates

Prevention of angina attacks by ivabradine

ACAM-2000 completes phase I trial

Omalizumab reduces the incidence of exacerbations in allergic asthma

Hybridon's IMO compounds show activity in preclinical models of allergic asthma

Catalyst Pharmaceutical will seek licenses for NM-702

Gadofosveset sodium improves MRA accuracy and patient management in PVD

Promising results emerge from phase II study of DP-b99 in stroke

Boston Scientific and Osiris form stem cell alliance

Mutual recognition procedure successfully completed for Crestor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...